Oxford Endovascular
Developing next-generation medical devices for neurovascular disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | £8.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Oxford Endovascular is a pioneering medical device company focused on developing next-generation solutions for neurovascular diseases, specifically targeting brain aneurysms. The company is currently in the GLP (Good Laboratory Practice) phase with its innovative brain aneurysm treatment device. This device aims to provide a safer and more effective treatment option for patients suffering from this life-threatening condition.
The primary clients for Oxford Endovascular are healthcare providers, including hospitals and specialized clinics that treat neurovascular conditions. The company operates in the medical technology (MedTech) market, which is a rapidly growing sector driven by advancements in medical science and technology.
Oxford Endovascular's business model revolves around the research, development, and commercialization of its medical devices. The company generates revenue through the sale of its devices to healthcare institutions. Additionally, it seeks funding through various channels, including grants, venture capital, and corporate investments, to support its research and development (R&D) activities and clinical trials.
The company has garnered significant recognition and support from the medical and investment communities. It has been a finalist in the RESI Innovation Challenge and has received substantial non-dilutive grant funding of up to 2.96 million Euros from EIT Health. This funding is crucial for advancing its R&D and clinical activities. Oxford Endovascular is also actively seeking additional investment, aiming to raise 8 million Euros to further its clinical trials and bring its device to market.
The leadership team at Oxford Endovascular is highly experienced, with CEO Mike Karim bringing over 30 years of expertise in medical devices and endovascular products. The Clinical Director, Professor James Byrne, has extensive clinical experience in treating aneurysms and a strong background in prototype development and device testing. Chairman Chas Taylor is a seasoned entrepreneur with a successful track record in founding and selling MedTech companies.
Keywords: neurovascular, brain aneurysm, medical device, healthcare, MedTech, innovation, R&D, clinical trials, investment, treatment.